Skip to main content
Journal cover image

A Phase II evaluation of weekly topotecan as a single agent second line therapy in persistent or recurrent carcinoma of the cervix: a Gynecologic Oncology Group study.

Publication ,  Journal Article
Fiorica, JV; Blessing, JA; Puneky, LV; Secord, AA; Hoffman, JS; Yamada, SD; Buekers, TE; Bell, J; Schilder, JM; Gynecologic Oncology Group,
Published in: Gynecol Oncol
November 2009

PURPOSE: To estimate antitumor activity and toxicity of weekly topotecan hydrochloride in patients with persistent or recurrent cervical carcinoma who failed prior treatment. PATIENTS AND METHODS: Women entered on study had or failed one prior chemotherapy regimen in addition to radiosensitizing chemotherapy, performance status less than 3, and adequate hematologic, renal, hepatic, and neurological function. Topotecan was infused at 3.0 mg/m(2) on days 1, 8, and 15 every 28 days. RESULTS: Twenty-seven patients were enrolled onto this study with 25 evaluable. Twenty-two patients had received radiation and chemotherapy prior to study. A median of two and mean of three courses of chemotherapy was given (range, one to eight courses). The most frequently severe adverse events were grade 3 anemia (28%) and grade 4 (4%) along with grade 3 neutropenia (8%) and grade 4 (8%). Two patients had grade 4 thrombocytopenia. There were no complete or partial responders. Ten patients (40%) had stable disease, twelve (48%) had increasing disease, and response could not be assessed in three (12%). The median progression-free survival was 2.4 months for the patients with increasing disease and 6.2 months (3.5-8.8 months) for those with stable disease. Disease location was equally divided within and outside the irradiated field. The 12 patients with increasing disease were more likely to have disease outside the pelvic radiation field. CONCLUSION: There were no complete or partial responders to weekly topotecan among the 25 patients in this study.

Duke Scholars

Published In

Gynecol Oncol

DOI

EISSN

1095-6859

Publication Date

November 2009

Volume

115

Issue

2

Start / End Page

285 / 289

Location

United States

Related Subject Headings

  • Uterine Cervical Neoplasms
  • Topotecan
  • Oncology & Carcinogenesis
  • Middle Aged
  • Humans
  • Female
  • Drug Administration Schedule
  • Antineoplastic Agents
  • Aged, 80 and over
  • Aged
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Fiorica, J. V., Blessing, J. A., Puneky, L. V., Secord, A. A., Hoffman, J. S., Yamada, S. D., … Gynecologic Oncology Group, . (2009). A Phase II evaluation of weekly topotecan as a single agent second line therapy in persistent or recurrent carcinoma of the cervix: a Gynecologic Oncology Group study. Gynecol Oncol, 115(2), 285–289. https://doi.org/10.1016/j.ygyno.2009.07.024
Fiorica, James V., John A. Blessing, Louis V. Puneky, Angeles Alvarez Secord, James S. Hoffman, S Diane Yamada, Thomas E. Buekers, Jeffrey Bell, Jeanne M. Schilder, and Jeanne M. Gynecologic Oncology Group. “A Phase II evaluation of weekly topotecan as a single agent second line therapy in persistent or recurrent carcinoma of the cervix: a Gynecologic Oncology Group study.Gynecol Oncol 115, no. 2 (November 2009): 285–89. https://doi.org/10.1016/j.ygyno.2009.07.024.
Fiorica JV, Blessing JA, Puneky LV, Secord AA, Hoffman JS, Yamada SD, et al. A Phase II evaluation of weekly topotecan as a single agent second line therapy in persistent or recurrent carcinoma of the cervix: a Gynecologic Oncology Group study. Gynecol Oncol. 2009 Nov;115(2):285–9.
Fiorica, James V., et al. “A Phase II evaluation of weekly topotecan as a single agent second line therapy in persistent or recurrent carcinoma of the cervix: a Gynecologic Oncology Group study.Gynecol Oncol, vol. 115, no. 2, Nov. 2009, pp. 285–89. Pubmed, doi:10.1016/j.ygyno.2009.07.024.
Fiorica JV, Blessing JA, Puneky LV, Secord AA, Hoffman JS, Yamada SD, Buekers TE, Bell J, Schilder JM, Gynecologic Oncology Group. A Phase II evaluation of weekly topotecan as a single agent second line therapy in persistent or recurrent carcinoma of the cervix: a Gynecologic Oncology Group study. Gynecol Oncol. 2009 Nov;115(2):285–289.
Journal cover image

Published In

Gynecol Oncol

DOI

EISSN

1095-6859

Publication Date

November 2009

Volume

115

Issue

2

Start / End Page

285 / 289

Location

United States

Related Subject Headings

  • Uterine Cervical Neoplasms
  • Topotecan
  • Oncology & Carcinogenesis
  • Middle Aged
  • Humans
  • Female
  • Drug Administration Schedule
  • Antineoplastic Agents
  • Aged, 80 and over
  • Aged